Cargando…

Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer

Samples in biobanks are generally preserved by formalin-fixation and paraffin-embedding (FFPE) and/or optimal cutting temperature compound (OCT)-embedding and subsequently frozen. Mass spectrometry (MS)-based analysis of these samples is now available via developed protocols, however, the difference...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valdés, Alberto, Bitzios, Athanasios, Kassa, Eszter, Shevchenko, Ganna, Falk, Alexander, Malmström, Per-Uno, Dragomir, Anca, Segersten, Ulrika, Lind, Sara Bergström
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027873/ https://www.ncbi.nlm.nih.gov/pubmed/33828141 http://dx.doi.org/10.1038/s41598-021-87003-6

Ejemplares similares

Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome
por: Mezheyeuski, Artur, et al.
Publicado: (2020)

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
por: Boman, Karolina, et al.
Publicado: (2013)

Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts
por: Andersson, Gustav, et al.
Publicado: (2014)

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
por: Kerzeli, Iliana K., et al.
Publicado: (2023)

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
por: Kerzeli, Iliana K., et al.
Publicado: (2021)

Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
por: Boman, K, et al.
Publicado: (2013)

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients
por: Chan, Owen T.M., et al.
Publicado: (2017)

The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer
por: Hemdan, T, et al.
Publicado: (2014)

PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity
por: Furuya, Hideki, et al.
Publicado: (2022)

Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours
por: Vedder, Moniek M., et al.
Publicado: (2014)

High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation
por: Wallach, J.B., et al.
Publicado: (2009)

Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma
por: Zeng, Shuxiong, et al.
Publicado: (2017)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Muscle RING-finger protein-1 (MuRF1) functions and cellular localization are regulated by SUMO1 post-translational modification
por: Heras, Gabriel, et al.
Publicado: (2018)

Can routine outpatient follow-up of patients with bladder cancer be improved? A multicenter prospective observational assessment of blue light flexible cystoscopy and fulguration
por: Zare, Reza, et al.
Publicado: (2018)

Serum Cystatin C Level Is Not a Promising Biomarker for Predicting Clinicopathological Characteristics of Bladder Urothelial Tumors
por: Wang, Hui, et al.
Publicado: (2018)

Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients
por: Mohanad, Marwa, et al.
Publicado: (2022)

Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database
por: Janopaul-Naylor, James Robert, et al.
Publicado: (2020)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders
por: Keay, Susan K., et al.
Publicado: (2014)

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides
por: Carlsson, Jörgen, et al.
Publicado: (2015)

Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)
por: Häggström, Christel, et al.
Publicado: (2017)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Role of angiogenesis in urothelial bladder carcinoma
por: Fus, Łukasz Piotr, et al.
Publicado: (2016)

Bladder melanosis with concurrent urothelial carcinoma
por: Yau, Susanna E., et al.
Publicado: (2017)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Giant Cell Urothelial Carcinoma of Bladder
por: Wijesinghe, Harshima Disvini, et al.
Publicado: (2021)

Molecular classification of urothelial bladder carcinoma
por: Schwarzova, Lucia, et al.
Publicado: (2023)

Image Analysis Based Grading of Bladder Carcinoma. Comparison of Object, Texture and Graph Based Methods and Their Reproducibility
por: Choi, Heung‐Kook, et al.
Publicado: (1997)

Urothelial Carcinoma of the Urinary Bladder in Young Adults: Presentation, Clinical behavior and Outcome
por: Nomikos, Michael, et al.
Publicado: (2011)

Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
por: Yang, Rui, et al.
Publicado: (2023)

FXYD3: A Promising Biomarker for Urothelial Carcinoma
por: Zhang, ZhongFa, et al.
Publicado: (2011)

ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
por: Mori, Keiichiro, et al.
Publicado: (2022)

Nested variant of urothelial carcinoma of the urinary bladder
por: Terada, Tadashi
Publicado: (2011)

CD10 expression in urothelial carcinoma of the bladder
por: Bahadir, Burak, et al.
Publicado: (2009)

Comprehensive molecular characterization of urothelial bladder carcinoma
Publicado: (2014)

Protein Profiling of Bladder Urothelial Cell Carcinoma
por: Hu, Jinghai, et al.
Publicado: (2016)

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer
por: Humayun-Zakaria, Nada, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_einjeubvp6h99s9rahh4v59arv